- Home
- NBTX vs TEAF Comparison
NBTX vs TEAF Comparison
Compare NBTX & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- TEAF
- Stock Information
- Founded
- NBTX 2003
- TEAF 2017
- Country
- NBTX France
- TEAF United States
- Employees
- NBTX N/A
- TEAF N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- NBTX Health Care
- TEAF Finance
- Exchange
- NBTX Nasdaq
- TEAF Nasdaq
- Market Cap
- NBTX 201.9M
- TEAF 174.8M
- IPO Year
- NBTX 2020
- TEAF N/A
- Fundamental
- Price
- NBTX $3.83
- TEAF $12.58
- Analyst Decision
- NBTX Strong Buy
- TEAF
- Analyst Count
- NBTX 2
- TEAF 0
- Target Price
- NBTX $11.50
- TEAF N/A
- AVG Volume (30 Days)
- NBTX 8.8K
- TEAF 56.1K
- Earning Date
- NBTX 11-26-2024
- TEAF 01-01-0001
- Dividend Yield
- NBTX N/A
- TEAF 9.20%
- EPS Growth
- NBTX N/A
- TEAF N/A
- EPS
- NBTX N/A
- TEAF N/A
- Revenue
- NBTX $45,220,186.00
- TEAF N/A
- Revenue This Year
- NBTX N/A
- TEAF N/A
- Revenue Next Year
- NBTX N/A
- TEAF N/A
- P/E Ratio
- NBTX N/A
- TEAF N/A
- Revenue Growth
- NBTX 526.17
- TEAF N/A
- 52 Week Low
- NBTX $3.57
- TEAF $11.11
- 52 Week High
- NBTX $8.96
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- NBTX 38.67
- TEAF 40.16
- Support Level
- NBTX $3.57
- TEAF $12.52
- Resistance Level
- NBTX $4.11
- TEAF $12.60
- Average True Range (ATR)
- NBTX 0.28
- TEAF 0.10
- MACD
- NBTX -0.00
- TEAF -0.01
- Stochastic Oscillator
- NBTX 26.31
- TEAF 36.28
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.